M S McQueney

Summary

Affiliation: SmithKline Beecham Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Autocatalytic activation of human cathepsin K
    M S McQueney
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Biol Chem 272:13955-60. 1997
  2. ncbi request reprint Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation
    M S McQueney
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, 19406, USA
    Protein Expr Purif 14:387-94. 1998
  3. ncbi request reprint Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K
    R W Marquis
    Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Bioorg Med Chem 7:581-8. 1999
  4. ncbi request reprint The crystal structure of human procathepsin K
    J M LaLonde
    Department of Structural Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Biochemistry 38:862-9. 1999
  5. ncbi request reprint Cyclic ketone inhibitors of the cysteine protease cathepsin K
    R W Marquis
    Department of Medicinal Chemistry, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA
    J Med Chem 44:725-36. 2001
  6. ncbi request reprint Expression in Escherichia coli, refolding, and purification of human procathepsin K, an osteoclast-specific protease
    K J D'alessio
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Protein Expr Purif 15:213-20. 1999
  7. ncbi request reprint Azepanone-based inhibitors of human and rat cathepsin K
    R W Marquis
    Department of Medicinal Chemistry, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, USA
    J Med Chem 44:1380-95. 2001
  8. ncbi request reprint cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy
    K M Anderson
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    J Mol Cell Cardiol 31:705-19. 1999
  9. ncbi request reprint Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro
    I E James
    Departments of Bone and Cartilage Biology, Medicinal Chemistry, Protein Biochemistry, and Mechanistic Enzymology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Biol Chem 276:11507-11. 2001
  10. pmc Design of potent and selective human cathepsin K inhibitors that span the active site
    S K Thompson
    Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Proc Natl Acad Sci U S A 94:14249-54. 1997

Detail Information

Publications11

  1. ncbi request reprint Autocatalytic activation of human cathepsin K
    M S McQueney
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Biol Chem 272:13955-60. 1997
    ..These results indicated that in vitro activation of the procathepsin K was an autocatalytic process...
  2. ncbi request reprint Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation
    M S McQueney
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, 19406, USA
    Protein Expr Purif 14:387-94. 1998
    ....
  3. ncbi request reprint Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K
    R W Marquis
    Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Bioorg Med Chem 7:581-8. 1999
    ....
  4. ncbi request reprint The crystal structure of human procathepsin K
    J M LaLonde
    Department of Structural Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Biochemistry 38:862-9. 1999
    ..The structure of procathepsin K contributes to an understanding of the molecular basis of inhibition by the propeptide portion of the molecule and activation of this important member of the cysteine protease family...
  5. ncbi request reprint Cyclic ketone inhibitors of the cysteine protease cathepsin K
    R W Marquis
    Department of Medicinal Chemistry, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA
    J Med Chem 44:725-36. 2001
    ..Epimerization issues associated with the labile alpha-amino ketone diastereomeric center contained within these inhibitor classes has proven to limit their utility despite promising pharmacokinetics displayed in both series of compounds...
  6. ncbi request reprint Expression in Escherichia coli, refolding, and purification of human procathepsin K, an osteoclast-specific protease
    K J D'alessio
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Protein Expr Purif 15:213-20. 1999
    ..This expression and refolding procedure yielded 50 mg of purified, glycosylation-free human procathepsin K from 1 liter of E. coli cell culture and enabled the determination of the structure of human procathepsin K at 2.6 A resolution...
  7. ncbi request reprint Azepanone-based inhibitors of human and rat cathepsin K
    R W Marquis
    Department of Medicinal Chemistry, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, USA
    J Med Chem 44:1380-95. 2001
    ....
  8. ncbi request reprint cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy
    K M Anderson
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    J Mol Cell Cardiol 31:705-19. 1999
    ..We report the novel findings that myotrophin expression is elevated in ischemic hearts, and that myotrophin expression correlates positively with ventricular mass in a hypoxic rat model of induced right ventricular hypertrophy...
  9. ncbi request reprint Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro
    I E James
    Departments of Bone and Cartilage Biology, Medicinal Chemistry, Protein Biochemistry, and Mechanistic Enzymology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Biol Chem 276:11507-11. 2001
    ..052 nm) and K (K(i) = 1.57 nm) was also active in both assays (IC(50) = 110 and 115 nm, respectively) These data confirm that cathepsin K and not cathepsin L is the major protease responsible for human osteoclastic bone resorption...
  10. pmc Design of potent and selective human cathepsin K inhibitors that span the active site
    S K Thompson
    Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Proc Natl Acad Sci U S A 94:14249-54. 1997
    ..Expansion of these inhibitor concepts can be envisioned for the many other cysteine proteases implicated for therapeutic intervention...
  11. ncbi request reprint An integrated ten-pump, eight-channel parallel LC/MS system for automated high-throughput analysis of proteins
    B Feng
    Department of Gene Expression and Protein Biochemistry, Discovery Research, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA
    Anal Chem 73:5691-7. 2001
    ..Using this off-line approach, it is practical to fully characterize protein-containing fractions from column chromatography with an overall analytical throughput of 1 min/protein sample with minimum operator involvement...